Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1WNGJ)

Drug Name

DFP-10917 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Acute lymphoblastic leukaemia	2A85	Phase 1/2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA replication (DNA repli)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[5]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[6]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[7]
Elliptinium acetate	DMZC6GT	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03926624) Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT00824161) Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT01702155) Phase I/II Study of DFP-10917 in Patients With Acute Leukemia. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
7	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8	Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.